Paper Details

  1. Home
  2. Paper Details

High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.

Author: HabererJessica, KanungiJennifer, KuoCaroline, MboguaJudie, MugoPeter, MutuaGaudensia, OperarioDon, PriddyFrances, SandersEduard Joachim, SinghSagri, Van der ElstElisabeth Maria

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

A study explored the experiences of men who have sex with men and female sex workers using oral PrEP for HIV prevention in Kenya. PrEP was found to be generally acceptable, with initial side effects improving over time. However, social stigma and challenges with adherence due to daily life complexities, particularly post-coital dosing, were noted. Consistent counseling addressing these issues could improve PrEP's effectiveness.
Paper Details　
Original Abstract of the Article :
This paper used qualitative methods to explore experiences of men who have sex with men and female sex workers in Nairobi and Mtwapa, Kenya, who used oral pre-exposure prophylaxis (PrEP) for HIV prevention as part of a four-month trial of safety, acceptability and adherence. Fifty-one of 72 voluntee...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23080358

データ提供：米国国立医学図書館（NLM）

HIV Pre-Exposure Prophylaxis (PrEP): Acceptability and Adherence in Kenya

HIV pre-exposure prophylaxis (PrEP) is a promising strategy for HIV prevention, offering individuals at risk a way to reduce their chances of infection. This study explores the acceptability and adherence to PrEP among men who have sex with men and female sex workers in Kenya, providing valuable insights into the challenges and opportunities of PrEP implementation in real-world settings.

The study found that PrEP was highly acceptable among participants, with most experiencing few side effects and finding the pill easy to use. However, adherence to PrEP was a significant challenge, influenced by social stigma, relationship difficulties, and the complexities of daily life. These findings underscore the importance of providing comprehensive support and counseling to ensure successful PrEP use.

Navigating the Challenges of PrEP Adherence

Imagine a camel caravan crossing a vast desert. Reaching its destination requires careful planning, consistent navigation, and a commitment to the journey. Similarly, PrEP adherence requires consistent effort and ongoing support to ensure its effectiveness in protecting individuals from HIV infection.

Culturally Tailored Approaches to PrEP Implementation

This study highlights the need for culturally appropriate and consistent counseling to address the specific challenges faced by individuals using PrEP. This involves creating a supportive environment that addresses social stigma, provides practical guidance on adherence, and empowers individuals to take ownership of their health.

Dr.Camel's Conclusion

PrEP is like a protective shield for those navigating the desert of HIV risk, but its effectiveness depends on consistent adherence, requiring a supportive environment and personalized guidance to overcome the challenges along the way.

Date :
  1. Date Completed 2013-08-30
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

23080358

DOI: Digital Object Identifier

NIHMS480969

Related Literature

Article Analysis
・Side Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.